StreetInsider.com News Articles

Codexis to Participate in Cantor Global Healthcare Conference 2026

Thu, 27 Aug 2026 09:00:00 -0400

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.

Management will participate in a fireside chat on Thursday, September 10, 2026, at 9:45 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, https://ir.codexis.com. A replay will be archived for 90 days following the

Codexis to Participate in Cantor Global Healthcare Conference 2026

Thu, 27 Aug 2026 09:00:00 -0400

Codexis to Participate in Cantor Global Healthcare Conference 2026

Thu, 27 Aug 2026 09:00:00 -0400

Codexis to Participate in Cantor Global Healthcare Conference 2026

Thu, 27 Aug 2026 09:00:00 -0400

Benchmark Reiterates Hold Rating on Codexis, Inc. (CDXS) Amid Transition to New Products/Services

Thu, 20 Aug 2026 09:18:14 -0400

Benchmark analyst Robert Wasserman reiterated a Hold rating and {REMOVEPT} price target on Codexis, Inc. (NASDAQ: CDXS).

The analyst commented, "Codexis reported in-line financial results for their 2Q26, including revenues of $14.9 million, down 3% year-overyear, with a reduced net loss of $12.0 million or ($0.13) per share as compared to $13.2 million or ($0.16) per share in 2Q26. Revenues were led in 2Q26 by $13.2 million from product sales, up from $7.4 million the prior year, offset by reduced R&D revenues of $1.7 million versus $7.9 million last year. Our estimates had been revenues of $14.5 million and a net

Codexis, Inc. (CDXS) PT Lowered to $8 at Piper Sandler

Mon, 17 Aug 2026 07:43:33 -0400

Piper Sandler analyst Do Kim lowered the price target on Codexis, Inc. (NASDAQ: CDXS) to $8.00 (from $9.00) while maintaining a Overweight rating.

Form SCHEDULE 13G/A CODEXIS, INC. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26919789.html

Form SCHEDULE 13G/A CODEXIS, INC. Filed by: LYTTON LAURENCE W

Thu, 13 Aug 2026 14:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26919789.html

Codexis (CDXS) Tops Q2 EPS by 1c

Tue, 11 Aug 2026 16:42:11 -0400

Codexis (NASDAQ: CDXS) reported Q2 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $14.92 million versus the consensus estimate of $13.82 million.

For earnings history and earnings-related data on Codexis (CDXS) click here.

Form 10-Q CODEXIS, INC. For: Jun 30

Tue, 11 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260811/26906125.html

Form 10-Q CODEXIS, INC. For: Jun 30

Tue, 11 Aug 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260811/26906125.html

Form 8-K CODEXIS, INC. For: Aug 11

Tue, 11 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26905813.html

Form 8-K CODEXIS, INC. For: Aug 11

Tue, 11 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26905813.html

Codexis Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:05:00 -0400

Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance

Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA

Completed successful equity capital raise of approximately $25 million in net proceeds

REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2026, and provided

Codexis Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:05:00 -0400

Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance

Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA

Completed successful equity capital raise of approximately $25 million in net proceeds

Codexis Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:05:00 -0400

Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance

Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA

Completed successful equity capital raise of approximately $25 million in net proceeds

Codexis Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 16:05:00 -0400

Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance

Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA

Completed successful equity capital raise of approximately $25 million in net proceeds

Codexis adds David Butler to its strategic advisory board

Mon, 03 Aug 2026 09:00:26 -0400

Codexis, Inc. (Nasdaq: CDXS) has appointed David Butler, PhD, to its Strategic Advisory Board, the company announced. Concurrently, Carole Cobb is stepping down from the board.

Butler brings more than 20 years of experience in the oligonucleotide field. He most recently served as Chief Technology Officer at Hongene Biotech Corporation from 2023 to 2026. Before that, he held chemistry leadership roles at Wave Life Sciences, Korro Bio, and Alltrna. Earlier in his career at Alnylam, he contributed to the development of liquid nanoparticle delivery technologies. He holds a BSc and PhD in Chemistry from St. Andrews University.

Alison Moore, PhD, President and

Codexis adds David Butler to its strategic advisory board

Mon, 03 Aug 2026 09:00:26 -0400

Codexis, Inc. (Nasdaq: CDXS) has appointed David Butler, PhD, to its Strategic Advisory Board, the company announced. Concurrently, Carole Cobb is stepping down from the board.

Alison Moore, PhD, President and

Codexis Appoints David Butler, PhD, to Strategic Advisory Board

Mon, 03 Aug 2026 09:00:00 -0400

REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the appointment of David Butler, PhD, to its Strategic Advisory Board (SAB). Dr. Butler will provide technical guidance, industry expertise, and strategic insight to support Codexis’ ongoing growth, innovation and core mission. Concurrently, Carole Cobb will be stepping down from the SAB.

“We are excited to have David join our SAB and look forward to the contributions he will make,” said Alison Moore, PhD., President and Chief

Codexis Appoints David Butler, PhD, to Strategic Advisory Board

Mon, 03 Aug 2026 09:00:00 -0400

“We are excited to have David join our SAB and look forward to the contributions he will make,” said Alison Moore, PhD., President and Chief

Codexis Appoints David Butler, PhD, to Strategic Advisory Board

Mon, 03 Aug 2026 09:00:00 -0400

“We are excited to have David join our SAB and look forward to the contributions he will make,” said Alison Moore, PhD., President and Chief

Codexis Appoints David Butler, PhD, to Strategic Advisory Board

Mon, 03 Aug 2026 09:00:00 -0400

“We are excited to have David join our SAB and look forward to the contributions he will make,” said Alison Moore, PhD., President and Chief

Form SCHEDULE 13G CODEXIS, INC. Filed by: Telemark Asset Management, LLC

Wed, 29 Jul 2026 15:55:00 -0400

si-local-file:///var/storage/secattach/20260729/26834649.html

Form SCHEDULE 13G CODEXIS, INC. Filed by: Telemark Asset Management, LLC

Wed, 29 Jul 2026 15:55:00 -0400

si-local-file:///var/storage/secattach/20260729/26834649.html